Answers are grounded in this paper and cite their sources.
Demonstrates the selection of CMY-219 resistance in E. coli, indicating potential risks for treatment failure.
Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing Escherichia coli ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.
No takes yet. Share an insight, caveat, or question.
Jousset et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: